Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
27.00 MCHF
−0.375CHF
−13.73 MCHF
33.56 MCHF
21.62 M
About KUROS N
Sector
Industry
CEO
Christopher T. Fair
Website
Headquarters
Schlieren
Employees (FY)
5
Founded
2000
ISIN
CH0325814116
FIGI
BBG006M6Z786
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of YTSN is 5.407 CHF — it has increased by 3.23% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange KUROS BIOSCIENCES stocks are traded under the ticker YTSN.
KUROS BIOSCIENCES is going to release the next earnings report on Aug 7, 2024. Keep track of upcoming events with our Earnings Calendar.
YTSN stock is 3.27% volatile and has beta coefficient of 2.00. Check out the list of the most volatile stocks — is KUROS BIOSCIENCES there?
YTSN earnings for the last quarter are −0.30 CHF per share, whereas the estimation was −0.38 CHF resulting in a 22.22% surprise. The estimated earnings for the next quarter are −0.33 CHF per share. See more details about KUROS BIOSCIENCES earnings.
KUROS BIOSCIENCES revenue for the last quarter amounts to 12.90 M CHF despite the estimated figure of 9.40 M CHF. In the next quarter revenue is expected to reach 18.70 M CHF.
Yes, you can track KUROS BIOSCIENCES financials in yearly and quarterly reports right on TradingView.
YTSN net income for the last quarter is −8.68 M CHF, while the quarter before that showed −5.05 M CHF of net income which accounts for −71.71% change. Track more KUROS BIOSCIENCES financial stats to get the full picture.
Today KUROS BIOSCIENCES has the market capitalization of 238.78 M, it has increased by 1.54% over the last week.
No, YTSN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, YTSN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KUROS BIOSCIENCES stock right from TradingView charts — choose your broker and connect to your account.
As of May 1, 2024, the company has 5.00 employees. See our rating of the largest employees — is KUROS BIOSCIENCES on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KUROS BIOSCIENCES technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KUROS BIOSCIENCES stock shows the buy signal. See more of KUROS BIOSCIENCES technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on KUROS BIOSCIENCES future price: according to them, YTSN price has a max estimate of 7.00 CHF and a min estimate of 7.00 CHF. Read a more detailed KUROS BIOSCIENCES forecast: see what analysts think of KUROS BIOSCIENCES and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KUROS BIOSCIENCES EBITDA is −6.15 M CHF, and current EBITDA margin is −18.33%. See more stats in KUROS BIOSCIENCES financial statements.